3rd Cell Engager Summit | June 30 - July 1, 2021 | Virtual Conference

The 3rd Annual Cell Engager Summit is the only industry-led forum dedicated to developing multi-specific cell engaging therapies in liquid and solid tumor indications, accelerating early discovery innovation into the clinic.

This forum comes at a critical point for the cell engager field as the success observed in the hematological field has not been obtained with solid tumors yet. Preclinical and early clinical data for cell engagers targeting solid tumors have been hugely promising.

If you are part of a research team that is looking to accelerate the approval of cell engager therapies, then this conference has been curated with you in mind.

Below are a few highlights you won't want to miss:

- Drive efficacy in solid tumors with solid tumor targets addressed by Roche, Amgen, Pfizer, Merus, and Compass Therapeutics
- Modulate the immune system to drive efficacy via co-stimulatory targets in solid tumors with Xencor, Harbour Biomed, Crescendo Biologics, Pieres, and Aptevo
- Harness the power of the innate system for cell engagers and overcome the tumor microenvironment with Merck, Lava Therapeutics, Verseau Tx, and oNKo-Innate
- Improving the therapeutic window of cell engagers - addressing toxicity, half-life, and CRS with Amunix, Synaffix, Revitope, and TeneoBio

Sound interesting? Download the full event guide for the complete conference agenda and speaker line-up. 

Prices:
Conference + Workshop - Drug Developer (Early Booking Rates Available): USD 2449.00,
Conference Only - Drug Developer (Early Booking Rates Available): USD 2099.00,
Conference + Workshop - Academic and Non Profit (Early Booking Rates Available): USD 2199.00,
Conference Only - Academic and Non Profit (Early Booking Rates Available): USD 1899.00,
Conference + Workshop - Solution Provider (Early Booking Rates Available): USD 3199.00,
Conference Only - Solution Provider (Early Booking Rates Available): USD 2799.00

Speakers: Pieter Fokko van Loo, Director Oncology Immunology, Merus, Christian Klein, Department Head Cancer Immunotherapy Discovery, Roche, Bryan Irving, Chief Scientific Officer, Amunix Pharmaceuticals, Andrew Pierce, VP Translational Biology, Crescendo Biologics, Nelly Kuklin, VP Immunology, Compass Therapeutics, Yiping Rong, Head of Discovery Biology, Harbour Biomed, Nicholas Huntington, Co-Founder and Chief Scientific Officer, oNKo-innate, Tatiana Novobrantseva, Co-Founder and Chief Scientific Officer, Verseau Therapeutics, Saileta Prabhu, VP/Global Head, Clinical Biomarker Innovation and Development, Takeda, David DiLillo, Associate Director, Regeneron Pharmaceuticals, Patricia Giblin, VP of Biology, Revitope Oncology, Maria Wendt, Head of Biologics Research and Global Head Digital Biologics Platform, Sanofi, Floris van Delft, Chief Scientific Officer, Synaffix, Fernanda Arnaldez, Executive Director - Medical and Global Clinical Development, MacroGenics, Wim van Schooten, Chief Scientific Officer, TeneoBio, Nathan Trinklein, Chief Technology Officer, TeneoBio, Chad May, SVP Research and Development, Maverick Therapeutics, Brian Rabinovich, Director, EMD Serono, Lukas Roth, Senior Scientist, Protein Engineering and Antibody Technologies, Merck KGaA, Michael Hedvat, Associate Director, Xencor, Inc., Joachim Koch, Head of Translational Research and Innovation, Affimed GmbH, Jane Gross, SVP and Chief Scientific Officer, Aptevo, Julie Bailis, Director of Research, Amgen, Jessica Kirshner, Senior Director Oncology, Regeneron Pharmaceuticals, Janet Peper, Senior Scientist, Translational Science, Pieris Pharmaceuticals, Divya Mathur, Director of Immuno-oncology, Regeneron Pharmaceuticals, Nuzhat Pathan, Director Early Development and Clinical Translation Immuno-oncology, Pfizer, Danielle Dettling, Senior Director, Pre- Clinical Pharmacology, Maverick, Gosia Nocula-Lugowska, Principal Scientist, Pfizer, Rick Austin, CSO, Harpoon Tx, Hans van der Vliet, CSO, Lava Tx, Bruce Keyt, Chief Scientific Officer, IGM Biosciences

Others Details

Time: 08:00 to 18:00 Brochure: https://go.evvnt.com/752419-3?pid=6581